Mercaptopurine Alternatives Compared
| Mercaptopurine | Entyvio (vedolizumab) | Pentasa (mesalamine) |
|
|---|
| Mercaptopurine | Entyvio (vedolizumab) | Pentasa (mesalamine) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Crohn's Disease - Maintenance, Autoimmune Hepatitis, Acute Lymphoblastic Leukemia, Crohn's Disease - Active, Inflammatory Bowel Disease, Intestinal Arterial Insufficiency, Ulcerative... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Prescribed for Ulcerative Colitis - Maintenance, Ulcerative Colitis - Active, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Proctitis, Ulcerative Colitis. Pentasa may also be... View more |
Related suggestions Crohn's Disease, Maintenance
|
|||||||||||||||||||||||
| More about Mercaptopurine | More about Entyvio (vedolizumab) | More about Pentasa (mesalamine) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Mercaptopurine has an average rating of 6.2 out of 10 from a total of 32 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 31% reported a negative effect. |
Entyvio has an average rating of 6.3 out of 10 from a total of 166 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
Pentasa has an average rating of 7.7 out of 10 from a total of 89 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Mercaptopurine side effects |
View all Entyvio side effects |
View all Pentasa side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mercaptopurine prices |
View all Entyvio prices |
View all Pentasa prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Purinethol, Purixan | Other vedolizumab brands include: Entyvio Pen | Other mesalamine brands include: Apriso, Asacol, Asacol HD, Canasa, Canasa Pac, Delzicol, Lialda, Rowasa, Rowasa Sulfite Free, Zaldyon View more | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
2 hours |
600 hours |
10 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
Excluding Asacol And Asacol HD
Category C
Risk cannot be ruled out
Asacol And Asacol HD See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 300 drugs are known to interact with Mercaptopurine:
|
A total of 169 drugs are known to interact with Entyvio:
|
A total of 121 drugs are known to interact with Pentasa:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
September 11, 1953 |
May 20, 2014 |
May 10, 1993 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Rasuvo
Rasuvo is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Ponatinib
Ponatinib is used to treat chronic myeloid leukemia and Philadelphia chromosome positive acute ...
Blinatumomab
Blinatumomab (Blincyto) is an injectable immunotherapy treatment that may be used to treat B-cell ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Imatinib
Imatinib is used to treat certain types of leukemia, bone marrow disorders, and skin cancer ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.